Difference between revisions of "Part:BBa K1456001"
Sayinorhan (Talk | contribs) |
Sayinorhan (Talk | contribs) |
||
| Line 2: | Line 2: | ||
<partinfo>BBa_K1456001 short</partinfo> | <partinfo>BBa_K1456001 short</partinfo> | ||
| − | + | ||
<ul> | <ul> | ||
<li>It has already been told that <b>this protein is the most potent and efficient thrombolytic agent popular in clinical practice.</b> It does this by activating plasminogen, a common anticoagulative factor zymogen found in normal bloodstream. By the conversion of plasminogen into plasmin, an enzyme that catalyzes the reaction of the cleavage of fibrin, the main clot component, <b>thrombolysis begins to degrade the clot.</b> (IUBMB Enzyme Nomeclature 1992; MetaCyc 2014) </li> | <li>It has already been told that <b>this protein is the most potent and efficient thrombolytic agent popular in clinical practice.</b> It does this by activating plasminogen, a common anticoagulative factor zymogen found in normal bloodstream. By the conversion of plasminogen into plasmin, an enzyme that catalyzes the reaction of the cleavage of fibrin, the main clot component, <b>thrombolysis begins to degrade the clot.</b> (IUBMB Enzyme Nomeclature 1992; MetaCyc 2014) </li> | ||
| Line 9: | Line 9: | ||
</ul> | </ul> | ||
| − | + | <center>[[File:ATOMS-tpa results10.jpg|400px|]]</center><br/> | |
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
Revision as of 15:31, 23 October 2014
Human Tissue Plasminogen Activator (htPA)
- It has already been told that this protein is the most potent and efficient thrombolytic agent popular in clinical practice. It does this by activating plasminogen, a common anticoagulative factor zymogen found in normal bloodstream. By the conversion of plasminogen into plasmin, an enzyme that catalyzes the reaction of the cleavage of fibrin, the main clot component, thrombolysis begins to degrade the clot. (IUBMB Enzyme Nomeclature 1992; MetaCyc 2014)
This activity has been shown synthetically in E.coli and experimentally in vitro. (Pennica et al. 1983; Van de Werf et al. 1984)
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NotI site found at 5
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 119
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI site found at 958